OptMed is a clinical-stage company that specializes in developing specialty healthcare products. With a strong emphasis on innovation, OptMed is focused on creating a line of surgical, biocompatible adhesives. Their lead product, BondEase® Topical Skin Adhesive, combines a unique proprietary polymer called methylidene malonate with advanced delivery technology.

OptMed utilizes a flexible, capital-efficient, and virtual business model to efficiently develop products generated by its platforms. Their strategic approach involves building value through product development and then commercializing those products through partnerships or sale. In December 2013, OptMed successfully completed a comprehensive clinical study with 162 patients.

This study, which was prospective, open-label, and randomized, aimed to evaluate the performance of BondEase® Topical Skin Adhesive. With an unwavering commitment to advancing healthcare solutions, OptMed is poised to make a significant impact in the field. Their dedication to innovation and collaboration sets them apart as a leading player in the development of specialty healthcare products